Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Amgen Inc. (AMGN : NSDQ)

• Company Description    Amgen Inc. is the leading biotech companies world wide, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health & nephrology and neuroscience markets. It developed two most successful drugs, Epogen & Neupogen. Amgen successfully launched two next-generation products, Aranesp & Neulasta and also a biosimilar drug, Prolia/Xgeva. The acquisition of Immunex Corp gave Amgen access to the multi-blockbuster drug, Enbrel. Other products are Repatha, Blincyto, Parsabiv, Evenity, Aimovig, Lumakras/Lumykras, Kanjinti, Mvasi & Amgevita biosimilars. Amgen also has a promising pipeline of cancer drugs. It has one of the strongest cash positions in the biotech sector, which could be used to acquire more pipeline assets that could fuel long-term growth. The erythropoiesis-stimulating agents and granulocyte colony-stimulating factor franchise comprise Epogen/Aranesp and Neupogen/Neulasta respectively. Biosimilar drugs are also a key part of Amgen's growth strategy. Number of Employees: 28,000

• Price / Volume Information    Yesterday's Closing Price: $379.73 Daily Weekly Monthly 20 Day Moving Average: 2,906,012 shares Shares Outstanding: 539.07 (millions) Market Capitalization: $204,700.16 (millions) Beta: 0.46 52 Week High: $385.12 52 Week Low: $261.43 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 10.52% 10.42% 12 Week 10.20% 9.10% Year To Date 16.01% 15.41%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL ONE AMGEN CENTER DRIVE - THOUSAND OAKS,CA 91320 USA ph: 805-447-1000 fax: 805-447-1010 investor.relations@amgen.com http://www.amgen.com

• General Corporate Information    Officers Robert A. Bradway - Chief Executive Officer; Chairman of the Board and Peter H. Griffith - Executive Vice President andChief Financial Office Matthew C. Busch - Vice President; Finance andChief Accounting Office Wanda M. Austin - Director Michael V. Drake - Director Peer Information Amgen Inc. (CORR.) Amgen Inc. (RSPI) Amgen Inc. (CGXP) Amgen Inc. (BGEN) Amgen Inc. (GTBP) Amgen Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 031162100 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 12/01/25 Next Expected EPS Date: 05/07/26 Share - Related Items Shares Outstanding: 539.07 Most Recent Split Date: 11.00 (2.00:1) Beta: 0.46 Market Capitalization: $204,700.16 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 2.65% Current Fiscal Quarter EPS Consensus Estimate: $4.78 Indicated Annual Dividend: $10.08 Current Fiscal Year EPS Consensus Estimate: $22.36 Payout Ratio: 0.44 Number of Estimates in the Fiscal Year Consensus: 15.00 Change In Payout Ratio: -0.01 Estmated Long-Term EPS Growth Rate: 4.37% Last Dividend Paid: 02/13/2026 - $4.90 Next EPS Report Date: 05/07/26

• Fundamental Ratios P/E Current FY Estimate: 16.98 Trailing 12 Months: 17.38 PEG Ratio: 3.89 Price Ratios Price/Book: 23.62 Price/Cash Flow: 11.23 Price / Sales: 5.57 EPS Growth vs. Year Ago Period: -0.38% vs. Previous Quarter: -6.21% Sales Growth vs. Year Ago Period: 8.58% vs. Previous Quarter: 3.23% ROE 12/31/25 - 148.37 09/30/25 - 162.59 06/30/25 - 174.71 ROA 12/31/25 - 13.23 09/30/25 - 13.18 06/30/25 - 13.12 Current Ratio 12/31/25 - 1.14 09/30/25 - 1.28 06/30/25 - 1.31 Quick Ratio 12/31/25 - 0.90 09/30/25 - 0.99 06/30/25 - 0.98 Operating Margin 12/31/25 - 32.21 09/30/25 - 32.92 06/30/25 - 33.82 Net Margin 12/31/25 - 20.98 09/30/25 - 19.47 06/30/25 - 18.96 Pre-Tax Margin 12/31/25 - 24.42 09/30/25 - 22.92 06/30/25 - 21.26 Book Value 12/31/25 - 16.06 09/30/25 - 17.86 06/30/25 - 13.81 Inventory Turnover 12/31/25 - 1.86 09/30/25 - 1.83 06/30/25 - 1.79 Debt-to-Equity 12/31/25 - 5.78 09/30/25 - 5.45 06/30/25 - 7.24 Debt-to-Capital 12/31/25 - 85.24 09/30/25 - 84.50 06/30/25 - 87.86

Powered by Zacks Investment Research ©